31684-74-9

Upstream product

• 65-85-0 benzoic acid 
• 87-62-7 2,6-dimethylaniline 
• 89210-36-6 3,5-dimethyl-4-nitrobenzophenone 
• 18109-39-2 N-(2,6-diimethylphenyl)benzamide 
• 81-20-9 2,6-dimethylnitrobenzene 
• 140-29-4 phenylacetonitrile 

Downstream Products

• 1196454-08-6 C₁₇H₁₆BrNO₂ 
• 31776-45-1 [4-(2-Ethoxy-ethylamino)-3,5-dimethyl-phenyl]-phenyl-methanone 

Relevant academic research and scientific papers

Ligand-based design and synthesis of novel sodium channel blockers from a combined phenytoin-lidocaine pharmacophore

The voltage-gated sodium channel remains a rich area for the development of novel blockers. In this study we used comparative molecular field analysis (CoMFA), a ligand-based design strategy, to generate a 3D model based upon local anesthetics, hydantoins

Novel quinolizidinyl derivatives as antiarrhythmic agents

Eighteen analogues of lidocaine, mexiletine, and procainamide were synthesized, replacing their aminoalkyl chains with the rigid and cumbersome quinolizidine nucleus. The target compounds were tested for antiarrhythmic, inotropic, and chronotropic effects

UREA AND THIOUREA COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES

The present invention relates to novel urea and thiourea compounds, compositions comprising urea or thiourea compounds, and methods useful for treating and preventing aging, Alzheimer’s Disease, cancer, cardiovascular disease, diabetic nephropathy, diabet

Urea and thiourea compounds and compositions for cholesterol management and related uses

The present invention relates to novel urea and thiourea compounds, compositions comprising urea or thiourea compounds, and methods useful for treating and preventing aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, enhancing bile production, enhancing reverse lipid transport, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, modulating C reactive protein, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), a thrombotic disorder, gastrointestinal disease, irritable bowel syndrome (IBS), inflammatory bowel disease (e.g., Crohn's Disease, ulcerative colitis), arthritis (e.g., rheumatoid arthritis, osteoarthritis), autoimmune disease (e.g., systemic lupus erythematosus), scleroderma, ankylosing spondylitis, gout and pseudogout, muscle pain: polymyositis/polymyalgia rheumatica/fibrositis; infection and arthritis, juvenile rheumatoid arthritis, tendonitis, bursitis and other soft tissue rheumatism. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

SURFACE PHOTOCHEMISTRY: THE AMIDE PHOTO-FRIES REARRANGEMENT

The Photo-Fries rearrangement of eight anilides on the surface of dry silica gel has been examined.The rearrangement occurs quite cleanly, giving somewhat more of the para isomer than that obtained in methanolic solution.A test for intermolecularity on the silica gel surface showed that, as in solution, the radical pair intermediates do not separate.This contrasts with the behaviour of a previously reported dibenzyl ketone derivate.